These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2584809

  • 1. [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
    Chen JT, Hirai Y, Nakayama K, Shimizu Y, Yokosuka K, Teshima H, Hamada T, Fujimoto I, Yamauchi K, Hasumi K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1565-70. PubMed ID: 2584809
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
    Chen JT, Hasumi K.
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):653-7. PubMed ID: 7717717
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B, Hansen OP, Hansen HH, Hansen M.
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [Abstract] [Full Text] [Related]

  • 4. [Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
    Tohnai I, Kawabe Y, Nakashima T, Yamagiwa M, Suzuki T, Mizuno A, Mineda H.
    Nihon Gan Chiryo Gakkai Shi; 1990 Oct 20; 25(10):2567-78. PubMed ID: 1702133
    [Abstract] [Full Text] [Related]

  • 5. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct 20; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 6. [Low-dose CDDP and 5-FU for head and neck cancer patients].
    Fujii M, Kanke M, Tomita T.
    Gan To Kagaku Ryoho; 1999 Oct 20; 26(11):1542-7. PubMed ID: 10553410
    [Abstract] [Full Text] [Related]

  • 7. [Effect of continuous infusion of 5-fluorouracil and daily low-dose cisplatin for inoperable recurrent cancer of the stomach and colon].
    Satoh Y, Une Y, Fujisawa J, Sawaguchi Y, Muranaga S, Obara M, Uchino J.
    Gan To Kagaku Ryoho; 1995 Jan 20; 22(1):87-92. PubMed ID: 7826083
    [Abstract] [Full Text] [Related]

  • 8. Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
    Kohno N, Ichikawa G, Shirasaka T, Inuyama Y, Kawaida M, Ohnuma T.
    Gan To Kagaku Ryoho; 1995 Aug 20; 22 Suppl 3():209-14. PubMed ID: 7661582
    [Abstract] [Full Text] [Related]

  • 9. [Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in locally advanced ovarian cancer].
    Shimizu Y, Fujiwara A, Akagaki E, Hirota K, Kono M, Irie T, Miura S, Okudaira Y.
    Gan To Kagaku Ryoho; 1986 May 20; 13(5):1934-9. PubMed ID: 3707153
    [Abstract] [Full Text] [Related]

  • 10. New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas.
    Chen JT, Hirai Y, Shimizu Y, Hasumi K, Masubuchi K.
    Gynecol Oncol; 1990 Jul 20; 38(1):1-5. PubMed ID: 2354814
    [Abstract] [Full Text] [Related]

  • 11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct 20; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 12. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N, Kitahara S, Tamura E, Tanabe T, Nakanoboh M, Kawada M, Shirasaka T.
    Gan To Kagaku Ryoho; 2000 May 20; 27 Suppl 2():592-9. PubMed ID: 10895216
    [Abstract] [Full Text] [Related]

  • 13. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 May 20; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 20; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 15. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
    Fujii M, Ohno Y, Tokumaru Y, Imanishi Y, Kanke M.
    Gan To Kagaku Ryoho; 1996 Nov 20; 23(13):1740-6. PubMed ID: 8937483
    [Abstract] [Full Text] [Related]

  • 16. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP, Song YS.
    Ann N Y Acad Sci; 2009 Aug 20; 1171():627-34. PubMed ID: 19723113
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of advanced bladder cancer with intra-arterial infusion of cisplatinum (CDDP) and aclacinomycin (ACR), combined with angiotensin II].
    Asahi T, Takeda K, Hayata S, Okita K, Akazawa N, Tsugawa M.
    Hinyokika Kiyo; 1987 Aug 20; 33(8):1167-71. PubMed ID: 3425516
    [Abstract] [Full Text] [Related]

  • 18. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
    Tsuji A, Morita S, Horimi T, Takasaki M, Takahashi I, Shirasaka T.
    Gan To Kagaku Ryoho; 1999 Jun 20; 26(7):933-8. PubMed ID: 10396320
    [Abstract] [Full Text] [Related]

  • 19. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G, Benasso M, Vannozzi MO, Merlano M, Rosso R, Viale M, Esposito M.
    Anticancer Res; 1998 Jun 20; 18(2B):1313-8. PubMed ID: 9615808
    [Abstract] [Full Text] [Related]

  • 20. [Weekly paclitaxel and cisplatin in recurrent ovarian cancer].
    Beppu M, Hiura M, Nogawa T, Yokoyama T, Kawakami Y, Chiba T.
    Gan To Kagaku Ryoho; 2001 May 20; 28(5):643-8. PubMed ID: 11383212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.